<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255775</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J0427, CDR0000450158</org_study_id>
    <secondary_id>P50CA058184</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0427</secondary_id>
    <secondary_id>JHOC-04051801</secondary_id>
    <nct_id>NCT00255775</nct_id>
    <nct_alias>NCT00090350</nct_alias>
  </id_info>
  <brief_title>Broccoli Sprout Extract in Preventing Lung Cancer in Smokers</brief_title>
  <official_title>Evaluation of the Biological Effects of Broccoli Sprout Extract in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs or substances to keep cancer from&#xD;
      forming, growing, or coming back. The use of broccoli sprout extract may prevent lung cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well broccoli sprout extract works in preventing&#xD;
      lung cancer in smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the effect of broccoli sprout extract on levels of DNA adducts in participants&#xD;
           who smoke.&#xD;
&#xD;
        -  Determine the effectiveness of broccoli sprout extract in reducing tobacco-carcinogen&#xD;
           induced DNA adducts in these participants.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effects of broccoli sprout extract on markers of the Nrf2 pathway in these&#xD;
           participants.&#xD;
&#xD;
        -  Determine the effectiveness of broccoli sprout extract, in increasing the activity of&#xD;
           the Nrf2 pathway, in these participants.&#xD;
&#xD;
        -  Evaluate the feasibility of using lymphocytes and buccal cells to monitor DNA adducts&#xD;
           and changes in the Nrf2 pathway in these participants.&#xD;
&#xD;
      OUTLINE: Participants are stratified according to GST genotypic polymorphism (M1 vs T1).&#xD;
&#xD;
      Participants receive oral broccoli sprout extract daily for 3 weeks. Participants keep a&#xD;
      daily diary of their eating and smoking habits for 3 weeks before, during, and for 3 weeks&#xD;
      after study treatment. They must continue to smoke during the study, but are encouraged to&#xD;
      quit after completing the study treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>broccoli sprout extract</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>complementary or alternative medicine procedure</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Current smoker with ≥ 30 pack-year history of smoking&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 4,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile participants must use effective contraception&#xD;
&#xD;
          -  No other medical condition that would preclude study treatment or compliance&#xD;
&#xD;
          -  No gastrointestinal condition that would affect absorption, preclude taking oral&#xD;
             medication, or necessitate IV alimentation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior surgery affecting absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 6 weeks since prior vitamins, herbal supplements, non-steroidal&#xD;
             anti-inflammatory drugs, or antibiotics&#xD;
&#xD;
          -  No concurrent dietary intake of cruciferous vegetables&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Brahmer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>August 5, 2010</last_update_submitted>
  <last_update_submitted_qc>August 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2010</last_update_posted>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

